Adrienne Beaudoin Deshmukh

Cooley advised Tempus AI (Nasdaq: TEM), a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare, on its agreement to acquire Ambry Genetics, a company focusing on genetic testing that aims to improve health by understanding the relationship between genetics and disease.

Cooley advised Adaptive Phage Therapeutics, a US-based, privately held, clinical-stage biotechnology company pioneering the development of phage-based therapies to combat bacterial infections, on its definitive merger agreement with BiomX, a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria.

Cooley advised Brii Biosciences on its agreements with VBI Vaccines (NASDAQ: VBIV) to ensure expansion and control of future clinical and commercial supplies of BRII-179, a late-stage clinical asset in Brii Bio’s hepatitis B virus functional cure portfolio. With operations in major biotechnology centers in the US and China, Brii Bio (HKSE: 2137) is a Hong Kong Stock Exchange-listed biotechnology company developing therapies to improve patient health and choice across diseases with high unmet needs.

Cooley advised Corporate Office Properties Trust on its agreement to sell its only multi-tenant data center, known as DC-6, to CloudHQ’s Cloud Capital for $222.5 million. Lawyers Michelle Garcia Schulman, Alanna Zuchelli and Adrienne Deshmukh led the Cooley team advising COPT, which is listed on the New York Stock Exchange under the symbol OFC.

Cooley advised Curv, a leading provider of cloud-based infrastructure for cryptocurrency security, on its agreement to sell to PayPal. Lawyers Derek Colla, Josh Holleman and Justin Rattigan led the Cooley team advising Curv.